<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Giant cell <z:mp ids='MP_0001856'>myocarditis</z:mp> (GCM) typically causes fulminant <z:hpo ids='HP_0001635'>heart failure</z:hpo>, <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, or <z:hpo ids='HP_0001678'>heart block</z:hpo>, necessitating aggressive immunosuppression, ventricular assist device insertion, or cardiac transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>We describe a novel variant of GCM, primarily involving the atria, that displays distinctive clinical features and follows a more benign course than ventricular GCM </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: We identified 6 patients (median age 67.5 years, 4 male) with atrial GCM in our pathology consultation practices from 2010 to 2012 </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical history, imaging, and pathology materials were reviewed </plain></SENT>
<SENT sid="4" pm="."><plain>Clinically, 4 patients had <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo>, 1 had <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001635'>heart failure</z:hpo>, and 1 had incidental disease at autopsy </plain></SENT>
<SENT sid="5" pm="."><plain>Among the 5 living patients, echocardiography revealed severe atrial <z:mpath ids='MPATH_66'>dilatation</z:mpath> (5 cases), mitral/<z:hpo ids='HP_0005180'>tricuspid regurgitation</z:hpo> (5), atrial <z:e sem="disease" ids="C0333205,C1260883" disease_type="Disease or Syndrome" abbrv="">mural thrombus</z:e> (3), atrial wall thickening (2), and atrial hypokinesis (2) </plain></SENT>
<SENT sid="6" pm="."><plain>Ventricular function was preserved in <z:hpo ids='HP_0000001'>all</z:hpo> 5 </plain></SENT>
<SENT sid="7" pm="."><plain>Histological review of surgically resected atria showed giant cell and lymphocytic infiltrates, lymphocytic <z:mp ids='MP_0001856'>myocarditis</z:mp>-like foci, <z:mp ids='MP_0010632'>cardiomyocyte necrosis</z:mp>, and cardiomyocyte <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="8" pm="."><plain>Other features included interstitial <z:mp ids='MP_0003045'>fibrosis</z:mp> (5), poorly-formed granulomas (4), eosinophils (4), neutrophils (1), and <z:hpo ids='HP_0002633'>vasculitis</z:hpo> (1) </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment consisted of steroids and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (1), pacemaker placement for <z:hpo ids='HP_0011704'>sick sinus syndrome</z:hpo> (1), and supportive care (3) </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 5 living patients returned to baseline exercise tolerance after 6 to 16 weeks of follow-up </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Atrial GCM represents a distinct clinicopathologic entity with a more favorable prognosis than classic ventricular GCM </plain></SENT>
<SENT sid="12" pm="."><plain>This disorder should be included in the differential diagnosis of atrial <z:mpath ids='MPATH_66'>dilatation</z:mpath>, particularly when associated with atrial wall thickening </plain></SENT>
<SENT sid="13" pm="."><plain>The utility of immunomodulatory therapy for this condition remains unknown </plain></SENT>
</text></document>